IHC of paraffin-embedded Carcinoma of Human liver tissue using anti-ERCC4 mouse monoclonal antibody.
ERCC4 / XPF Antibody (clone OTI4E11)
Primary AntibodyLSBio Guarantee
| Antibody: | Mouse Monoclonal |
| Applications: | Flow Cytometry, Immunofluorescence, Immunohistochemistry (general), Immunohistochemistry, Paraffin, Western Blot |
| Reactivity: | Human, Mouse |
| Format: | Liquid |
$443.00each
Catalog Number: LS-C173159-100
Catalog Number: LS-C173159
For bulk orders or custom formulations:
Request a QuoteOverview
- Description
- XPF antibody LS-C173159 is an unconjugated mouse monoclonal antibody to XPF (ERCC4) from human. It is reactive with human and mouse. Validated for Flow, IF, IHC and WB. Cited in 1 publication.
- Application
- FC, IF, IHC, IHC-P, WB
- Reactivity
- Hu, Ms
- Intended Use
- Research Use Only
- Guarantees
- This antibody carries the LSBio 100% Guarantee. ✓
- Category
- Antibodies > Primary Antibodies > Monoclonal Antibodies
- Alternative Names
- ERCC11 | ERCC4 | DNA repair endonuclease XPF | XPF
- Recommended Dilution: FC
- 1:100
- Recommended Dilution: IF/ICC
- 1:100
- Recommended Dilution: IHC-P
- 1:150
- Recommended Dilution: WB
- 1:500 - 1:2000
- UniProt Number
- Q92889
- NCBI GenBank
- AAB50174.1 | L77890
- SwissProt
- Q92889
Target
- Target
- Human ERCC4 / XPF
- Antigen Species
- Human
- Epitope
- Human ERCC4 / XPF
- Gene Name
- ERCC4
Antibody
- Host Species
- Mouse
- Clonality
- Monoclonal
- Clone
- OTI4E11
- Isotype
- IgG2a
Immunogen
- Immunogen
- Full length human recombinant protein of human ERCC4(NP_005227) produced in HEK293 cell.
- Immunogen Type
- Full-Length Recombinant Protein
Format
- Conjugate/Label
- Unconjugated
- Format
- Liquid
- Formulation
- PBS, pH 7.3, 0.02% Sodium Azide, 50% Glycerol, 1% BSA
- Volume
- 100 Microliter
- Preservative
- Yes
- Purification Method
- Protein A/G Affinity
Storage & Handling
- Storage Conditions
- Store at -20°C. Avoid freeze-thaw cycles.
- Recommended Storage Buffer
- PBS
Modulation of ERCC1-XPF Heterodimerization Inhibition via Structural Modification of Small Molecule Inhibitor Side-Chains. Claudia Weilbeer, David Jay, James C Donnelly, Francesco Gentile, Feridoun Karimi-Busheri, Xiaoyan Yang, Rajam S Mani, Yaping Yu, Ahmed H Elmenoufy, Khaled H Barakat, Jack A Tuszynski, Michael Weinfeld, Frederick G West. Frontiers in oncology. 2022 April;12:819172. PubMed: 35372043 PMC: PMC8968952